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Abstract
Background: Early recognition and risk stratification are crucial in cardiogenic shock (CS). A lower adherence to
recommendations has been described in women with cardiovascular diseases. Little information exists about
disparities in clinical picture, management and performance of risk stratification tools according to gender in
patients with CS.
Methods: Data from the multicenter Red-Shock registry were used. All consecutive patients with CS were included.
Both CardShock and IABP-SHOCK II risk scores were calculated. The primary end-point was in-hospital mortality. The
discriminative ability of both scores according to gender was assessed by binary logistic regression, calculating
Receiver operating characteristic (ROC) curves and the corresponding area under the curve (AUC).
Results: A total of 793 patients were included, of whom 222 (28%) were female. Women were significantly older
and had a lower proportion of chronic obstructive pulmonary disease and prior myocardial infarction. CS was less
often related to acute coronary syndromes (ACS) in women. The use of vasoactive drugs, renal replacement
therapy, invasive ventilation, therapeutic hypothermia and mechanical circulatory support was similar between both
groups. In-hospital mortality was 346/793 (43.6%). Mortality was not significantly different according to gender (p =
0.194).
Cardshock risk score showed a good ability for predicting in-hospital mortality both in man (AUC 0.69) and women
(AUC 0.735). Likewise, the IABP-II successfully predicted in-hospital mortality in both groups (man: AUC 0.693;
women: AUC 0.722).
Conclusions: No significant differences were observed regarding management and in-hospital mortality according
to gender. Both the CardShock and IABP-II risk scores depicted a good ability for predicting mortality also in
women with CS.
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Background
Cardiogenic shock (CS) is a severe clinical condition that
leads to a high mortality (40–59%) despite the treatment
advances made in the last decade, including early myo-
cardial reperfusion in myocardial infarction (MI) [1–3].
Early recognition and risk stratification are crucial for
both patient allocation and selection of the optimal
treatment strategy [4]. The recently developed Card-
Shock [1] and IABP-SHOCK II [5] risk scores contain
variables that can be easily obtained at the bedside or
with routine laboratory tests, and have been recently val-
idated in a large cohort of non-selected patients with CS
from a Spanish multicenter registry.
On the other hand, significant differences regarding
clinical profile, management and prognosis according to
gender have been previously described in patients with
cardiovascular disease [6–9]. Importantly a significantly
lower adherence to current recommendations has been
consistently described in other clinical scenarios, espe-
cially in patients with Acute Coronary Syndromes (ACS)
[10, 11]. Little information exists about clinical picture,
management and prognosis according to gender in pa-
tients with CS.
Therefore, the aim of this study was to describe the
clinical picture, management and the predictive ability of
the Cardshock and IABP-II risk scores according to gen-
der in patients with CS from routine clinical practice.
Methods
Study design and inclusion criteria
Red-Shock registry [12] is an observational, retrospect-
ive, cohort study. The design has been previously de-
scribed [12]. Consecutive patients aged 18 years or older
with cardiogenic shock ((a) systolic blood pressure < 90
mmHg (after adequate fluid challenge) for 30 min or
need for vasopressor therapy to maintain systolic blood
pressure > 90mmHg, and b) signs of hypoperfusion)
were included. Patients with shock after cardiac or non-
cardiac surgery or ongoing haemodynamically significant
arrhythmia as the cause of hypotension were excluded.
The study was approved by the reference research eth-
ics committee and was conducted in accordance with
the Declaration of Helsinki. Because the study was retro-
spective, informed consent was not required. Patients
were treated according to the current practice of each
center.
Data collection
Demographic characteristics, clinical profile at admission
(within 6 h after the onset of CS) and treatments admin-
istered were recorded.
Both the CardShock [1] and the IABP-SHOCK II [5]
risk scores were calculated in the study cohort. An opti-
mal thrombolysis in myocardial infarction (TIMI) flow
was considered by default (0 points) in non ACS
patients.
Outcomes
Main outcome measured was in-hospital mortality ac-
cording to gender status.
Statistical analysis
Baseline characteristics and clinical management were
assessed according to gender. Categorical variables were
reported as frequencies and percentages, and statistical
differences were analysed by using the χ2 test. Continu-
ous variables were reported as the mean and standard
deviation or the median and interquartile range; statis-
tical differences were analysed using the Student t test
or Wilcoxon test, as appropriate.
The discriminative ability of the CardShock score and
the IABP-II score were assessed by a binary regression
logistic model, calculating Receiver operating character-
istic (ROC) curves and the corresponding area under the
curve (AUC). For the performance of this analysis only
patients with available Cardshock and IABP-II scores
values were included (n = 696). Comparison between
AUCs was performed by the DeLong method [13]. Cali-
bration of the scores was assessed by the Hosmer-
Lemeshow test. A P-value < 0.05 was considered signifi-
cant and all statistical analyses were performed using
STATA software, version 13.1 (Stata Corp, College Sta-
tion, TX, USA).
Ethics statement
All procedures performed in this study were in accord-
ance with the ethical standards of the institutional re-
search committee and with the 1964 Helsinki
declaration and its later amendments or comparable eth-
ical standards. This study was approved by the reference
institutional ethics comittee).
Results
A total of 793 patients with CS were included from 6
centers, of whom 222 (28%) were female. Mean age was
65.1 ± 15 years. A high proportion of comorbidities was
observed, such as hypertension (58.8%) diabetes mellitus
(39.6%), prior MI (20.1%) or previous heart failure
(26.9%). In most cases (501/793, 63.2%) CS was related
to ACS.
Patients had a high risk profile, with a severely de-
pressed left ventricular function, high proportion of con-
fusion at presentation, elevated lactate values and low
values of estimated glomerular filtration (eGFR)
(Table 1).
Collado-Lledó et al. BMC Cardiovascular Disorders          (2020) 20:189 Page 2 of 8
Clinical characteristics according to gender status
Women were significantly older, were less often active
smokers and had a significantly lower proportion of co-
morbidities such as chronic obstructive pulmonary dis-
ease (COPD) and prior MI (Fig. 1). CS was less often
related to ACS in women. A slightly better left ventricu-
lar function was observed in this group, as well as lower
values of lactate at admission and higher values of eGFR.
No significant differences were observed regading the
CardShock and IABP II risk scores values according to
gender status.
Clinical management according to gender status
The proportion of use of vasoactive drugs was not
significantly different in both groups, except for a
less common utilisation of dobutamine and a higher
prescription of milrinone in women. Likewise, the
rate of utilisation of in-hospital invasive procedures
(renal replacement therapy, invasive ventilation,
therapeutic hypothermia) was similar between both
groups. Mechanical circulatory support was also used
with a similar proportion in men and women
(Table 2).
Table 1 Clinical characteristics according to gender status
Whole cohort (n = 793) Male (n = 571) Female (n = 222) P value
Age 65.1 (15) 64.2 (14) 67.3 (16) 0,013
BMI 26.9 (5) 27 (4) 26.7 (6) 0.537
Diabetes mellitus 314 (39.6) 226 (39.6) 88 (39.6) 0.988
Hypertension 466 (58.8) 331 (58) 135 (61.1) 0.424
Dyslipidemia 446 (56.2) 329 (57.6) 117 (52.7) 0.210
Active smoker 219 (27.7) 190 (33.4) 29 (13.1) 0.001
COPD 130 (16.4) 108 (18.9) 22 (9.9) 0.002
Prior stroke 69 (8.7) 54 (9.5) 15 (6.8) 0.226
PAD 90 (11.3) 71 (12.4) 19 (8.6) 0.122
Prior MI 159 (20.1) 126 (22.1) 33 (14.9) 0.023
Prior PCI 96 (12.1) 74 (13) 22 (9.9) 0.485
Prior CABG 33 (4.2) 24 (4.2) 9 (4.1) 0.789
Renal failure 134 (16.9) 104 (18.2) 30 (13.5) 0.113
Previous heart failure 213 (26.9) 150 (26.3) 63 (28.5) 0.524
ACS-related cardiogenic shock 501 (63.2) 373 (65.3) 128 (57.7) 0.044
Systolic blood pressure 81 (16) 81 (16) 80 (15) 0.969
Heart rate 94 (28) 94 (29) 93 (27) 0.459
Cardiac arrest 176 (22.2) 132 (23.1) 44 (19.9) 0.330
Sinus rythm 565 (72.3) 404 (71.6) 161 (74.2) 0.473
LVEF (%) 32 (13) 31 (13) 34 (13) 0.003
Confusion at presentation 486 (61.4) 352 (61.8) 134 (60.4) 0.717
Lactate 0.056
< 2 mmol/L 169 (23.8) 128 (24.9) 41 (21)
2–4 mmol/L 213 (30) 162 (31.5) 51 (26.2)
> 4 mmol/L 328 (46.2) 225 (43.7) 103 (52.8)
Glucose > 191mg/dL 357 (46.9) 252 (45.8) 105 (49.8) 0,329
eGFR (ml/min/1.73 m2) 0.027
< 30 146 (24.3) 90 (20.9) 56 (32.7)
30–60 271 (45) 205 (47.6) 66 (38.6)
> 60 185 (30.7) 136 (31.6) 49 (28.7)
CardShock score value 4.7 (1.7) 4.7 (1.7) 4.8 (1.8) 0.501
IABP II score value 2.5 (1.8) 2.5 (1.8) 2.6 (1.8) 0.525
BMI Body mass index, COPD Chronic obstructive pulmonary disease, PAD Peripheral artery disease, MI Myocardial infarction, PCI percutaneous coronary
intervention, CABG Coronary artery bypass grafting, ACS Acute Coronary Syndrome, LVEF Left Ventricle Ejection Fraction, eGFR estimated glomerular filtration rate
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In-hospital mortality and predictive ability of Cardshock
and IABP-II risk scores according to gender
In-hospital mortality for the overall cohort was 346/793
(43.6%). Mortality was not significantly different accord-
ing to gender (47.3% vs 42.2%, p = 0.194). Mortality was
more commonly due to cardiac causes (76.2%, vs 61.4%)
and less commonly due to severe neurologic damage in
men (4.8% vs 12%, p = 0.027).
Cardshock risk score showed a good ability for pre-
dicting in-hospital mortality both in man (AUC 0.69,
95% CI 0.6547–0.739) and women (AUC 0.735, 95% CI
0.663–0.806). Likewise, the IABP-II successfully
predicted in-hospital mortality in both groups (AUC in
man 0.693, 95% CI 0.647–0.739; women AUC 0.722,
95% CI 0.649–0.795). The predictive ability of both
scores was not significantly different according to
gender.
Calibration was also acceptable for both scores in both
groups (supplementary Table 1). Figure 2 shows the
ROC curves for the prediction of in-hospital mortality of
the Cardshock score in man (2a) and women (2b). Fig-
ure 3 shows the ROC curves for the prediction of in-
hospital mortality of the IABP-II risk score in men (3a)
and women (3b).
Contribution of each components of the Cardshock and
IABP-II scores to in-hospital mortality according to gender
In man, the components of the Cardshock with a stron-
ger association with mortality were confusion at presen-
tation, lactate levels and glomerular filtration. Left
ventricular disfunction was also significantly associated
with mortality, while the association between age > 75
years and mortality had a non-significant trend. In con-
trast, the association between previous MI or coronary
artery bypass surgery and ACS etiology with mortality
was clearly not significant (supplementary Table 2). In
contrast, in women only lactate levels and glomerular
Table 2 Clinical management according to gender status
Whole cohort (n = 793) Male (n = 571) Female (n = 222) P value
Vasoactive drugs
Dobutamine 716 (90.3) 530 (92.8) 186 (83.8) 0.001
Dopamine 62 (7.8) 42 (7.4) 20 (9) 0.435
Adrenaline 132 (16.6) 95 (16.6) 37 (16.7) 0.992
Noradrenaline 620 (78.2) 444 (77.8) 176 (79.3) 0.436
Levosimendan 75 (9.5) 59 (10.3) 16 (7.2) 0.177
Milrinone 16 (2) 6 (1.1) 10 (4.5) 0.004
Invasive procedures
Renal replacement therapy 150 (19) 105 (18.5) 45 (20.3) 0.558
Invasive mechanical ventilation 489 (61.7) 358 (62.7) 131 (59) 0.617
Non invasive mechanical ventilation 77 (9.7) 53 (9.3) 24 (10.8) 0.597
Therapeutic hypothermia 43 (5.4) 35 (6.1) 8 (3.6) 0.158
Swan-Ganz catheter 273 (34.4) 191 (33.5) 82 (36.9) 0.353
Intraaortic counterpulsation 370 (46.7) 274 (48) 96 (43.2) 0.229
ECMO 67 (8.4) 53 (9.3) 14 (6.3) 0.176
Impella® 30 (3.8) 23 (4) 7 (3.2) 0.562
Levitronix centrimag® 55 (6.9) 40 (7) 15 (6.8) 0.902
Revascularization 0.426
None 334 (42.1) 233 (40.8) 101 (45.5)
PCI 433 (54.6) 320 (56) 113 (50.9)
Surgical 26 (3.3) 18 (3.2) 8 (3.6)
PCI Percutaneous coronary intervention
Fig. 1 Baseline clinical characteristics according to gender status
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filtration were significantly associated with mortality
(supplementary Table 2).
Likewise, significant differences were observed regard-
ing the specific contribution of each of the components
of the IABP-II score for predicting mortality according
to gender. While in man age, creatinine, lactate levels
and TIMI flow grade in culprit lesion were significantly
associated to in-hospital mortality, in women this associ-
ation with mortality was observed only for creatinine
and lactate levels (supplementary Table 3).
Discussion
Main findings from this study are: a) around one of each
three of these patients with CS from routine clinical
Fig. 2 ROC curves for the prediction of in-hospital mortality of the Cardshock score in man (a) and women (b)
Fig. 3 ROC curves for the prediction of in-hospital mortality of the IABP-II risk score in men (a) and women (b)
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practice were women; b) female patients with CS were
older, and CS was less commonly ACS-related in this
group; c) both clinical management and in-hospital mor-
tality were similar regardless gender status, and d) both
the CardShock and IABP-II risk scores depicted a good
ability for predicting mortality in both sexes.
CS is a severe clinical condition with a very high mor-
tality despite continuous therapeutic advances. Clinical
evidence regarding the optimal management in these
complex patients is scarce. The few randomized trials [3,
14, 15] addressing patients with CS showed negative re-
sults, and literature is mostly base in heterogeneous ob-
servational studies addressing ACS-related CS [16–21].
The proportion of women in these series ranges between
25 and 45%, with mean ages ranging between 65 and 80
years [16–22].
This series included one of the youngest populations
of CS patients, with a relatively low proportion of
women as compared to previous data. This could be re-
lated to the fact that this study included highly selected
patients from high complexity centers, with consolidated
heart transplantation and advanced heart failure pro-
grams in most cases. Importantly, almost 40% of patients
had non-ACS related CS, in contrast to most published
CS series [16–22].
Women with cardiovascular disease have been clearly
under represented in clinical trials, and the evidence re-
garding their optimal clinical management in different
clinical scenarios is scarce, especially in patients with
ACS. Most data come from observational studies show-
ing that women are usually older, have a high degree of
comorbidities, a lower adherence to current recommen-
dations and a higher mortality [10, 11]. Information
about differences in clinical characteristics, management
and outcomes according to gender in CS patients is
scarce. Most of the few series show that women with CS
are usually older [1, 16–22]. However, differences re-
garding the proportion of comorbidities between men
and women are not so evident as compared to patients
with ACS. This is especially remarkable in series of pa-
tients undergoing advanced therapies at high complexity
centers, probably because of a likely selection bias.
In an interesting contribution, Hayıroğlu et al. [23]
assessed predictors of in-hospital mortality in 319 pa-
tients with MI complicated with CS. Despite a trend to a
higher proportion of women was observed among non-
survivors, gender showed no significant association with
mortality in the multivariate analysis. Likewise, in a
series of 544 patients with STEMI with CS undergoing
primary PCI, Cheng et al. [24] described a significant as-
sociation between female gender and mortality in uni-
variable analysis. However, only age, baseline lactate
creatinine levels remained independent predictors of 30-
day mortality in the multivariable analysis.
Women from this series were significantly older, but
the proportion of important comorbidities such as dia-
betes, prior stroke or peripheral artery disease was not
significantly different between both groups. Indeed, the
proportion of comorbidities such as COPD and prior MI
was lower in women. Interestingly, the proportion of
ACS-related CS was significantly lower in women.
A significant concern exists about the lower adherence
to recommendations in women with cardiovascular
disease, especially in ACS. Likewise, in women with
acute heart failure intensive medical and interventional
therapies are also underutilized [25]. Information about
management disparities in women with CS is scarce.
Abdel-Qadir et al. [20] assessed a series of 9750 patients
with ACS-related CS from the Ontario Myocardial In-
farction Database. The authors described that women
with CS were less likely to present to revascularization-
capable sites, were less often revascularized and less
likely to be transferred when they presented to non-
revascularization sites.
Improving this gender related disparities is one of the
major challenges for the upcoming years. In this sense,
the implementation of standardized ST segment eleva-
tion myocardial infarction (STEMI) protocol and
Systems has been associated to a reduction of health
care differences and mortality in women with ACS [26].
On the other hand, management at high volume special-
ized centers has been associated to a better adherence to
recommendations and lower mortality in patients with
CS [27]. In an interesting study, Iantorno et al. [21]
assessed a series of 8845 consecutive adult patients ad-
mitted to a tertiary coronary care unit, of whom 42.1%
were women. A similar pulmonary artery catheter (PAC)
use according to gender was observed (11.3% in women
and 11.5% in men). In CS patients, PAC use rates in
women and men were also similar (50.3% vs 49.1%) The
authors concluded that full-time intensivist staffing
might contribute to reduce gender-based treatment
disparities.
As stated before, management disparities seem to be
lower in highly selected patients requiring advanced sup-
port measures. Joseph et al. [18] described a series of
180 patients from the cVAD Registry who underwent
percutaneous coronary intervention (PCI) and Impella
2.5 support for CS complicating an acute MI, of whom
49 (27.2%) were women. Despite women were older, the
proportion of important comorbidities such as diabetes,
prior MI, PAD or renal dysfunction was not significantly
different according to gender. No differences in timing
to intervention were found between men and women.
The number of inotropes and the proportion of mechan-
ical ventilation and intraaortic counterpulsation were
not significantly different in both groups. There was no
difference in survival to discharge (p = 0.3). Interestingly,
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the magnitude of the survival benefit was significantly
greater in women who received the Impella pre-PCI as
compared to men.
Consistently with these data, we did not observe in
our patients significant differences regarding vasoactive
drugs prescription and use of in-hospital invasive proce-
dures according to gender. In our opinion, this might be
mostly related to the high degree of selection of CS pa-
tients from this series (especially women with CS), as
well as the fact of being treated at high complexity aca-
demic hospitals. This similar management patterns ac-
cording to gender might have contributed to the similar
mortality observed in both groups.
Patients with stablished shock criteria and high lactate
levels have a significantly higher mortality. Therefore,
early risk stratification is crucial step in order to select
the optimal clinical management. Recently two risk
scores have been published to predict short-term mor-
tality in patients with CS: the CardShock risk score [1],
derived from a multicentre cohort of ACS and non-ACS
patients, and the IABP-SHOCK II risk score [5], derived
from a clinical trial performed in acute MI patients
undergoing percutaneous coronary intervention (PCI).
Both scores have shown good discrimination for short-
term mortality. It is important to note that gender is not
a component in either CardShock or IABP-SHOCK risk
scores. To our knowledge no study addressed the poten-
tial disparities of risk stratification according to gender
in patients with CS. This is an interesting point, since
women were under represented in the populations form
whom both scores were derived. Data from this study
showed a good ability for predicting in-hospital mortality
from both scores in both women and men. Therefore,
both the Cardshock and the IABP-II scores should be
considered useful tools also in women with CS.
Other predictive factors have been described in pa-
tients with CS. Information for the coronary anatomy
can also contribute to predict outcomes in CS pa-
tients. In this sense, recently a combination of clinical
and angiographic factors by the SYNTAX score II
showed also a significant predictive ability for predict-
ing mortality in STEMI patients with CS undergoing
primary PCI [28].
This study has some limitations, such as its moderate
sample size and its observational nature, so we cannot
rule the effect of unmeasured confounding. Patients
were mostly admitted to high complexity hospitals with
heart transplantation and advanced heart failure pro-
grams, which may lead to a significant selection bias.
Therefore, our findings should be validated in larger
series of non-selected CS patients admitted to other type
of centers. However, we believe that despite these limita-
tions this study retrieves novel and interesting data
about the clinical picture, management and risk
stratification of patients with CS according to gender.
Improving clinical outcomes of these complex patients
may lead to potential important social and economic
consequences.
Conclusions
About one of each three of these patients with CS from
routine clinical practice were women. Female patients
with CS were older, and CS was less commonly ACS-
related in this group. No significant differences were ob-
served regarding management and in-hospital mortality
according to gender. Both the CardShock and IABP-II
risk scores depicted a good ability for predicting mortal-
ity also in women with CS.
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